We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects.
- Authors
Tanhapour, Maryam; Golestani, Abolfazl; Vaisi-Raygani, Asad; Aminian, Mahdi
- Abstract
Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment. Recent studies have introduced a mutant of diphtheria toxin, cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts for the stimulation of cell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor. This study has focused on the structure, properties, and anticancer activity of CRM197.
- Subjects
ANTINEOPLASTIC agents; DIPHTHERIA toxin; EPIDERMAL growth factor receptors; HEPARIN
- Publication
Basic & Clinical Cancer Research, 2021, Vol 13, Issue 1, p1
- ISSN
2228-6527
- Publication type
Article